Q4 EPS Estimates for Globus Medical Raised by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Zacks Research lifted their Q4 2027 EPS estimates for Globus Medical in a research report issued to clients and investors on Thursday, August 27th. Zacks Research analyst Team now expects that the medical device company will earn $1.37 per share for the quarter, up from their previous estimate of $1.22. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $4.99 per share. Zacks Research also issued estimates for Globus Medical’s FY2028 earnings at $5.88 EPS.

GMED has been the topic of a number of other research reports. Piper Sandler lowered their target price on Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a research report on Monday, June 15th. UBS Group began coverage on Globus Medical in a research report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price target for the company. Wells Fargo & Company decreased their price target on Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Royal Bank Of Canada lowered their price target on Globus Medical from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Finally, BMO Capital Markets began coverage on Globus Medical in a research note on Wednesday, July 8th. They set an “outperform” rating and a $94.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $101.77.

Globus Medical Price Performance

Globus Medical stock opened at $80.32 on Monday. The firm has a 50-day moving average of $81.18 and a 200-day moving average of $84.49. Globus Medical has a one year low of $54.15 and a one year high of $101.40. The company has a market cap of $10.78 billion, a price-to-earnings ratio of 20.54, a P/E/G ratio of 1.31 and a beta of 0.95.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The business had revenue of $789.61 million during the quarter, compared to the consensus estimate of $782.88 million. During the same quarter last year, the firm earned $0.86 earnings per share. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS.

Insider Activity

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director owned 510,175 shares of the company’s stock, valued at $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen T. Zarrilli sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares in the company, valued at approximately $2,176,000. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 18.38% of the company’s stock.

Institutional Trading of Globus Medical

A number of hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System increased its holdings in shares of Globus Medical by 7,827.7% during the 2nd quarter. California State Teachers Retirement System now owns 10,326,607 shares of the medical device company’s stock worth $815,905,000 after acquiring an additional 10,196,347 shares during the last quarter. Janus Henderson Group PLC raised its stake in Globus Medical by 4.5% in the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after acquiring an additional 328,217 shares during the period. Invesco Ltd. lifted its holdings in Globus Medical by 1,235.2% during the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after purchasing an additional 3,595,339 shares during the last quarter. Bank of Montreal Can lifted its holdings in Globus Medical by 15,317.1% during the 4th quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock valued at $294,519,000 after purchasing an additional 3,351,380 shares during the last quarter. Finally, Sculptor Capital LP boosted its position in Globus Medical by 1.9% during the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock worth $263,477,000 after purchasing an additional 58,000 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.